Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

p> patients. Preliminary data from this trial will be presented at the

American Society of Clinical Oncology meeting in June.

Genzyme is developing a new filing for the adult AML indication in

Europe. This follows its withdrawal of Bioenvision's marketing

application, which, as expected, an advisory committee deemed

insufficient to support approval. Genzyme expects to make a new

submission as early as the fourth quarter of this year that will

include a more robust data package from Genzyme sponsored studies.

Alemtuzumab for multiple sclerosis

-- Final, three-year efficacy and safety data from the Phase 2 trial

comparing alemtuzumab with Rebif (interferon beta-1a) for the treatment

of relapsing-remitting multiple sclerosis were presented last week

during a scientific platform session at the American Academy of

Neurology meeting by Dr. Alasdair Coles. These results confirm all

trends observed in the one- and two-year interim analyses. The two

ongoing Phase 3 trials further examining the efficacy and safety of

alemtuzumab for the treatment of MS are progressing. These two studies

are currently enrolling patients at sites in the United States, Europe,

Latin America and Australia. Genzyme believes that alemtuzumab has the

potential to be the best therapy in a market for MS drugs that is

projected to reach $8-9 billion annually when the treatment is expected

to be ready for launch in 2011-2012. Alemtuzumab is being developed in

collaboration with Bayer Schering Pharma AG, Germany.

Genz-112638 for Gaucher disease

-- Genzyme is making excellent progress in developing the small molecule

Genz-112638, a novel oral therapy intended for the treatment of Gaucher

disease. Initial results released one year ago for the first group of

stud
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... March 30, 2015  Naldemedine, an investigational peripherally ... Shionogi & Co., Ltd., met its primary and ... I) for the treatment of opioid-induced constipation (OIC) ... opioid therapy. Study results showed that naldemedine (0.2 ... the frequency of spontaneous bowel movement (SBM) compared ...
(Date:3/29/2015)... , March 29, 2015 Caris ... important study data showing the presence of ... gynecologic cancer samples. Using Caris Molecular Intelligence®, ... researchers identified expression of programmed cell death ... of histology while its ligand (PD-L1) expression ...
(Date:3/27/2015)... , March 27, 2015  Neogen Corporation (NASDAQ: ... adopted a prearranged trading plan in accordance with Securities ... Chairman and CEO of Neogen Corporation, is a minority ... Corporation common stock. Herbert does not have ... appropriate. The filing is only for a portion of ...
(Date:3/27/2015)... Md. , March 27, 2015  CASI Pharmaceuticals, ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a commercial focus on ... three and 12 months ended December 31, 2014.  ... ($1.6 million), or ($0.05) per share, for the three ...
Breaking Biology Technology:Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Neogen CEO adopts 10b5-1 Trading Plan 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6
... Investment Conference on... -- HARBIN, China, Sept. 7 /PRNewswire-Asia-FirstCall/ -- ... ... --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Calif., Sept. 7 / PRNewswire/ -- Transdel ... announced that Transdel management will present a company overview at ... York City on Monday, September 13, 2010 at 4:05 p.m. ... webcast via the Internet by visiting the Investor Relations section ...
... Exclusive Partnership Agreements for Immunotherapy Tablets in Japan -- ANTONY, France, September 6, 2010 ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology Technology:Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 2Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 3Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 4Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 5Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 6Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 7Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference 2Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference 3Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 2Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 3Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 4Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 5Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 6Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 7Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 8Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 9
(Date:3/18/2015)... 2015 As mobile payments become more ... wallets and apps continue to be introduced into the market ... mobile payment industry in focus today are:  NXT-ID, Inc. (NASDAQ: ... BABA ), Apple Inc. (NASDAQ: AAPL ), ... (NASDAQ: FB ) NXT-ID, Inc. (NASDAQ: ...
(Date:3/12/2015)... , March 12, 2015 IriTech, a ... a member of the Texas Instruments Design Network, announced ... has demonstrated its IriShield USB MK2120U device during ... facility for pension distribution. The iris ... to be marketed in India ...
(Date:3/11/2015)... --  The Sync Project™ today announced the ... harness music to improve health. The platform maps ... of physiology, enabling the study of the therapeutic ... It is designed for medical and health research, ... and accelerate the discovery of the clinical applications ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... combine forces? Individuals with chronic myeloid ... as imatinib (Gleevec), which targets the protein known to ... BCR-ABL mutants emerge that are resistant to the effects ... as dasatinib (SPRYCEL), which targets BCR-ABL in a different ...
... A detailed map that pinpoints the location of every ... evolutionary steps needed to create the molecules modern version, ... at Chapel Hill and the University of Oregon. ... the proteins and other molecules necessary for life have ...
... having kids to help raise the offspring of others ... reproduce, but many African starlings have adopted this strategy ... habitats, according to a new study by University of ... the Aug. 21 issue of the journal Current Biology. ...
Cached Biology News:JCI table of contents: Aug. 16, 2007 2JCI table of contents: Aug. 16, 2007 3JCI table of contents: Aug. 16, 2007 4JCI table of contents: Aug. 16, 2007 5JCI table of contents: Aug. 16, 2007 6JCI table of contents: Aug. 16, 2007 7Structure of 450 million year old protein reveals evolution's steps 2Savanna habitat drives birds, and perhaps others, to cooperative breeding 2Savanna habitat drives birds, and perhaps others, to cooperative breeding 3Savanna habitat drives birds, and perhaps others, to cooperative breeding 4
Mouse Aminopeptidase P2/XPNPEP2 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
... 53 new primer sets added in Dec ... than 3 hours , Detection from ... , Specific primers available for hundreds ... either real-time or end-point RT-PCR , ...
AGAROSE PREP, 50G, 1 EA. Category: Genephor Precast Gels....
in vitro Translation, Accessory Products...
Biology Products: